| Literature DB >> 23363438 |
Huili Wang1, Yanmei Yang, Wei Chen, Li Ding, Peizhen Li, Xiaokai Zhao, Xuedong Wang, Aiying Li, Qiyu Bao.
Abstract
Arthrospira (Spirulina) platensis as a representative species of cyanobacteria has been recognized and used worldwide as a source of protein in the food, which possesses some unusual and valuable physiological characteristics, such as alkali and salt tolerance. Based on complete genome sequencing of Arthrospira (Spirulina) plantensis-YZ, we compared the protein expression profiles of this organism under different salt-stress conditions (i.e. 0.02 M, 0.5 M and 1.0 M NaCl, respectively), using 2-D electrophoresis and peptide mass fingerprinting, and retrieved 141 proteins showing significantly differential expression in response to salt-stress. Of the 141 proteins, 114 Arthrospira (Spirulina) plantensis-YZ proteins were found with significant homology to those found in Arthrospira (76 proteins in Arthrospira platensis str. Paraca and 38 in Arthrospira maxima CS-328). The remaining 27 proteins belong to other bacteria. Subsequently, we determined the transcriptional level of 29 genes in vivo in response to NaCl treatments and verified them by qRT-PCR. We found that 12 genes keep consistency at both transcription and protein levels, and transcription of all of them but one were up-regulated. We classified the 141 differentially expressed proteins into 18 types of function categories using COG database, and linked them to their respective KEGG metabolism pathways. These proteins are involved in 31 metabolism pathways, such as photosynthesis, glucose metabolism, cysteine and methionine metabolism, lysine synthesis, fatty acid metabolism, glutathione metabolism. Additionally, the SRPs, heat shock protein and ABC transporter proteins were identified, which probably render Arthrospira (Spirulina) plantensis's resistance against high salt stress.Entities:
Year: 2013 PMID: 23363438 PMCID: PMC3599948 DOI: 10.1186/1477-5956-11-6
Source DB: PubMed Journal: Proteome Sci ISSN: 1477-5956 Impact factor: 2.480
Figure 1The differential protein points between medium salt (0.5 M NaCl) treatment and the control (0.02 M NaCl). (Note: (A) The differential protein points with >3.0-fold changes in medium salt (0.5 M NaCl) treatment compared with the control (0.02 M NaCl). (B) The protein-spots of absent or present difference between the two groups (the relative abundance (Vol%) of “present” protein calculated by the ratio of volume of each protein spot to volume of total protein spots in the whole gel,ranging from 0.928% to 8.06% as shown in Additional file 1: Table S3-B).
Figure 2The differential protein points between high salt (1.0 M NaCl) treatment and control (0.02 M NaCl). (Note: (A) The differential protein points with >3.0-fold changes in high salt (1.0 M NaCl) treatment group compared to control (0.02 M NaCl). (B) The protein-spots of absent or present difference between the two groups (the relative abundance (Vol%) of “present” protein calculated by the ratio of volume of each protein spot to volume of total protein spots in the whole gel,ranging from 1.208% to 11.872%, as shown in Additional file 1: Table S3-D).
Figure 3The differential protein points between high salt (1.0 M NaCl) treatment and medium salt (0.5 M NaCl) treatment. (Note: (A) The differential protein points with >3.0-fold changes in high salt (1.0 M NaCl) treatment compared to medium salt (0.5 M NaCl) treatment. (B) The protein-spots of absent or present difference between the two groups (the relative abundance (Vol%) of “present” protein calculated by the ratio of volume of each protein spot to volume of total protein spots in the whole gel, ranging from 2.170% to 22.854%, as shown in Additional file 1: Table S3-F).
Figure 4COG functional classification of 132 positive differential expression proteins.
Annotation and proposed metabolic pathways of the differential protein spots obtained from the MS-searching
| CK701 | M718 | 3277 | ZP_03275759 | FAD-dependent pyridine nucleotide disulphide oxidoreductase [ | 47147/42726 | 6.67/6.49 | 6 | 20% | 78 | 0.018 | −4.70 |
| CK275 | M305 | 2281 | ZP_06380867 | Peptidyl-prolyl cis-trans isomerase, cyclophilintype[ | 23921/28931 | 4.74/4.49 | 6 | 36% | 75 | 0.036 | −3.65 |
| M908 | H653 | 2287 | ZP_03274434 | Molecular chaperone DnaK [ | 62452/57079 | 4.70/5.57 | 27 | 38% | 150 | 1.00E-09 | 3.65 |
| CK461 | H-N | 4535 | ZP_06381408 | GDP-L-fucose synthase [ | 35652/35258 | 5.59/6.14 | 23 | 53% | 260 | 1.00E-20 | / |
| CK361 | H-N | 5055 | ZP_06383266 | Enoyl-(acyl carrier protein) reductase [ | 27751/31814 | 5.57/5.83 | 11 | 37% | 79 | 0.013 | / |
| M344 | H224 | 1433 | YP_002521548 | 3-oxoacyl-[acyl-carrier protein] reductase [ | 28631/31269 | 6.54/5.34 | 9 | 34% | 73 | 0.049 | 3.24 |
| CK47 | H-N | 4103 | ZP_03271327 | Phycobilisome core component [ | 17433/14807 | 6.26/5.74 | 14 | 84% | 165 | 3.30E-11 | / |
| CK342 | M394 | 2155 | ZP_06382427 | Phycobilisome linker polypeptide [ | 29450/31199 | 9.25/5.68 | 15 | 55% | 218 | 1.6E-16 | −3.26 |
| CK423 | H-N | 4633 | ABV01983 | Cpch [ | 30852/33929 | 7.82/6.29 | 25 | 60% | 295 | 3.30E-24 | / |
| CK467 | H342 | 4632 | ABB84420 | Cpci [ | 32790/35621 | 8.33/4.59 | 19 | 53% | 150 | 1.00E-09 | 3.09 |
| CK-N | H69 | 4634 | ZP_06380686 | Phycocyanin, alpha subunit [ | 17703/19259 | 5.82/5.89 | 10 | 58% | 91 | 0.00076 | / |
| CK-N | M252 | 4635 | ABD64607 | Phycocyanin beta chain [ | 18506/28381 | 5.19/4.58 | 11 | 55% | 98 | 0.00016 | / |
| CK-N | M137 | 1911 | ZP_06383116 | Adenylylsulfate kinase [ | 19897/22320 | 5.22/5.46 | 16 | 79% | 200 | 1e-14 | / |
| CK-N | M463 | 3910 | ZP_06382240 | Dihydrodipicolinate synthase [ | 30869/34837 | 5.20/5.80 | 22 | 51% | 141 | 8.3e-09 | / |
| CK500 | M548 | 4030 | ZP_03276569 | Diaminopimelate epimerase [ | 32452/37662 | 9.22/6.83 | 39 | 76% | 310 | 1e-25 | 3.56 |
| CK517 | H384 | 4938 | ZP_06381009 | Glutathione synthetase [ | 36159/38491 | 5.93/6.64 | 15 | 43% | 100 | 0.0001 | 4.04 |
| CK-N | M595 | 3807 | ZP_03274253 | Glyceraldehyde-3-phosphate dehydrogenase, type I [ | 36534/39635 | 6.07/5.26 | 24 | 61% | 110 | 0.00001 | / |
| M778 | H545 | 1688 | ZP_06381331 | Adenosylhomocysteinase [ | 46667/45550 | 5.64/5.98 | 25 | 52% | 245 | 3.3e-19 | 3.26 |
| CK145 | M140 | 2740 | ZP_06381970 | F-type H+-transporting ATPase subunit delta [ | 20108/22132 | 6.15/6.79 | 15 | 53% | 116 | 2.6e-06 | 3.77 |
| CK109 | M93 | 2739 | ZP_03274295 | F-type H+-transporting ATPase subunit β[ | 19538/17970 | 5.14/5.04 | 13 | 59% | 114 | 4.2e-06 | 3.28 |
| M800 | H564 | 2050 | ZP_03275033 | ABC-type nitrate/nitrite transport system substrate-binding protein [ | 48859/47107 | 4.68/4.46 | 26 | 50% | 235 | 3.30E-18 | 3.57 |
| M-N | H185 | 4213 | YP_798213 | Signal recognition particle subunit SRP54[ | 49178/28565 | 7.08/5.46 | 8 | 24% | 74 | 0.046 | / |
| M111 | H-N | 1989 | | Transcriptional regulator, abrb family [ | 15532/19479 | 8.49/4.22 | 11 | 44% | 90 | 0.0011 | / |
| CK934 | M-N | 1251 | ZP_06381540 | Hypothetical protein aplap_07632 [ | 67407/65336 | 5.66/6.20 | 19 | 42% | 166 | 2.6E-11 | / |
| CK424 | M-N | 5516 | ZP_03272395 | Conserved hypothetical protein [ | 41116/34016 | 6.04/6.08 | 13 | 50% | 205 | 3.3E-15 | / |
| CK283 | M-N | 3023 | ZP_06383801 | Hypothetical protein AplaP_19221 [ | 23973/29221 | 7.03/6.22 | 9 | 58% | 94 | 0.00044 | / |
| CK202 | H127 | 1198 | ZP_06382670 | Hypothetical protein aplap_13413 [ | 29241/25864 | 8.15/5.52 | 11 | 54% | 103 | 5.2e-05 | 4.70 |
| CK-N | M175 | 273 | ZP_06384609 | Hypothetical protein aplap_23383 [ | 20229/25353 | 5.93/5.71 | 9 | 49% | 121 | 8.3e-07 | / |
| M839 | H591 | 624 | ZP_06384828 | Hypothetical protein aplap_24525 [ | 37661/50381 | 4.91/5.25 | 27 | 61% | 226 | 2.60E-17 | 3.99 |
Note: (1) 0.02 M NaCl for control group (CK); 0.5 M NaCl for medium salt treatment (M); and 1.0 M NaCl for high salt treatment (H).
(2) CK-N, M-N and H-N represent no protein-spots are observed in control, medium and high salt treatment groups, respectively.
(3) The grey mark indicates up-regulation of proteins.
(4) The negative values in fold column indicate the down-regulation.
(5) T/E indicates theoretical values/experimental values.
Figure 5qRT-PCR identification of 29 differential expression genes between the control (0.02 M NaCl) and the medium salt (0.5 M NaCl) treatment. (Note: * indicates the significant difference, at p<0.05 level, of the transcriptional levels between medium salt treatment (0.5 M NaCl) and the control (0.02 M NaCl), and ** indicates the extremely significant difference at p<0.01 level).
The comparison between qPCR and proteomic analyzing result
| 3277 | UR >8 | DR>4(0.5 M and control) | No |
| 2281 | UR >27 | DR>3(0.5 M and control) | No |
| 4535 | UR >12 | DR>3(1.0 M and control) | No |
| 5055 | UR >40 | DR>3(0.5 M and 1.0 M treatment) | No |
| 4103 | UR >142017 | DR>3(1.0 M and control) | No |
| 1911 | DR>4 | DR>3(0.5 M and control) | No |
| 4633 | UR >2 | DR>3(0.5 M and control) | No |
| 2155 | UR >11 | DR>3 (0.5 M and control) | No |
| 4030 | UR >3 | UR>3(0.5 M and control) | Yes |
| 1989 | UR >50406 | DR<3(0.5 M and 1.0 M treatment) | No |
| 1251 | UR >425003 | DR<3(0.5 M and control) | No |
| 5516 | UR >27288 | DR<3(0.5 M and control) | No |
| 3023 | UR >14294 | DR<3(0.5 M and control) | No |
| 3910 | UR >960 | UR<3(0.5 M and control) | Yes |
| 4938 | UR >4 | UR>4(1.0 M and control) | Yes |
| 3807 | UR >2 | UR<3(0.5 M and control) | Yes |
| 1688 | UR >2 | UR>3(0.5 M and 1.0 M treatment) | Yes |
| 2740 | UR >20 | UR>3(0.5 M and control) | Yes |
| 2739 | UR >3 | UR>3(0.5 M and control) | Yes |
| 1433 | UR >5 | UR>3 (0.5 M and 1.0 M treatment) | Yes |
| 2287 | UR >194 | UR>3(0.5 M and 1.0 M treatment) | Yes |
| 2050 | UR >13 | UR>3(0.5 M and 1.0 M treatment) | Yes |
| 4213 | UR >4 | UR>3(0.5 M and 1.0 M treatment) | Yes |
| 4632 | UR >2 | UR>3(1.0 M and control) | Yes |
| 4634 | UR >2 | UR>3(1.0 M and control) | Yes |
| 4635 | UR >1846 | UR>3(0.5 M and control) | Yes |
| 273 | UR >158255 | UR>3(0.5 M and control) | Yes |
| 1198 | UR >9 | UR>4(1.0 M and control) | Yes |
| 624 | UR >25867164 | UR>3(0.5 M and 1.0 M treatment) | Yes |
UR and DR indicate up-regulation and down-regulation, respectively.